Rocuronium (rapid onset-curonium) is a desacetoxy analogue of vecuronium with a more rapid onset of action. It is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Introduced in 1994, rocuronium has rapid onset, and intermediate duration of action. It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. However, there was a similar incidence of allergic reactions associated with other non-depolarizing neuromuscular blocking agents. Sugammadex is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.
For inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
National Cancer Institute, Cairo, Egypt
Rigshospitalet, Glostrup, Glostrup, Denmark
Rigshospitalet, Copenhagen, Denmark
UHCZagreb, Zagreb, Croatia
Elite Medical Center, Kuwait, Kuwait
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
WVU Medicine, Morgantown, West Virginia, United States
Hopital Maisonneuve Rosemont, CIUSSS de l'Est de l'Ile de Montréal, Montréal-Est, Quebec, Canada
AOU Mater Domini, Catanzaro, Italy
Parkland Health & Hospital System, Dallas, Texas, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.